Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: A possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation

被引:35
作者
Ruggenenti, Piero
Codreanu, Igor
Cravedi, Paolo
Perna, Annalisa
Gotti, Eliana
Remuzzi, Giuseppe
机构
[1] Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy
[2] Azienda Osped Riuniti Bergamo, Dept Med & Transplantat, Bergamo, Italy
[3] Republ Clin Hosp, Dept Haemodialysis & Kidney Transplantat, Chisnau, Moldova
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 1卷 / 03期
关键词
D O I
10.2215/CJN.01841105
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In high-risk kidney transplant recipients, induction therapy with rabbit anti-human thymocyte globulin (RATG) reduces the risk for acute rejection but is associated with significant toxicity, opportunistic infections, and cancer. Using reduced doses of RATG combined with anti-IL-2 antibodies may achieve the same antirejection activity of standard-dose RATG but with a better safety profile. This randomized, open-label study compared the efficacy, tolerability, and costs of low-dose RATG (0.5 mg/kg per d) plus basiliximab (20 mg 4 d apart) versus standard-dose RATG (2 mg/kg per d) in 33 consecutive high-risk renal transplant recipients (living-related transplant recipients, sensitized patients or patients who received another transplant, and patients with delayed graft function) over 6 mo of follow-up. All patients received concomitant therapy with steroids, cyclosporin A, and azathioprine or mycophenolate mofetil. Seventeen patients received low-dose RATG plus basiliximab, and 16 received standard-dose RATG. Patient (100 versus 100%) and graft (94 versus 100%) survival were comparable in the two groups, but the incidence of fever (17.6 versus 56.5%; P = 0.01), leukopenia (23.5 versus 56.3%; P < 0.05), anemia (29.4 versus 62.5%; P < 0.05), cytomegalovirus reactivations (17.6 versus 56.5%; P = 0.01), the number of transfused units (0.5 +/- 0.9 versus 2.0 +/- 2.4; P < 0.001), and treatment costs (3652 +/- 704 versus 5400 +/- 1960 euro; P = 0.001) were lower with low-dose RATG plus basiliximab than with standard-dose RATG. There was one episode of biopsy-proven acute rejection on low-dose RATG plus basiliximab, and there were two on standard-dose RATG. In renal transplantation, induction therapy with basiliximab plus low-dose RATG effectively prevents acute rejection and is safer and more cost-effective than induction with standard-dose RATG.
引用
收藏
页码:546 / 554
页数:9
相关论文
共 43 条
[1]   Short course induction immunosuppression with thymoglobulin for renal transplant recipients [J].
Agha, IA ;
Rueda, J ;
Alvarez, A ;
Singer, GG ;
Miller, BW ;
Flavin, K ;
Lowell, JA ;
Shenoy, S ;
Howard, TK ;
Ramachandran, V ;
Irish, W ;
Schnitzle, MA ;
Brennan, DC .
TRANSPLANTATION, 2002, 73 (03) :473-475
[2]   PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL-ANTIBODY USED IN CADAVERIC RENAL-TRANSPLANTATION [J].
AMLOT, PL ;
RAWLINGS, E ;
FERNANDO, ON ;
GRIFFIN, PJ ;
HEINRICH, G ;
SCHREIER, MH ;
CASTAIGNE, JP ;
MOORE, R ;
SWENY, P .
TRANSPLANTATION, 1995, 60 (07) :748-756
[3]   Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) [J].
Bacigalupo, A ;
Lamparelli, T ;
Bruzzi, P ;
Guidi, S ;
Alessandrino, PE ;
di Bartolomeo, P ;
Oneto, R ;
Bruno, B ;
Barbanti, M ;
Sacchi, N ;
Van Lint, MT ;
Bosi, A .
BLOOD, 2001, 98 (10) :2942-2947
[4]   EFFECT OF CYCLOSPORINE AND DELAYED GRAFT FUNCTION ON POSTTRANSPLANTATION ERYTHROPOIESIS [J].
BESARAB, A ;
CARO, J ;
JARRELL, B ;
BURKE, J ;
FRANCOS, G ;
MALLON, E ;
KARSCH, R .
TRANSPLANTATION, 1985, 40 (06) :624-631
[5]  
Brennan DC, 2001, J AM SOC NEPHROL, V12, P848, DOI 10.1681/ASN.V124848
[6]   Leukocyte response to thymoglobulin or Atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients [J].
Brennan, DC ;
Flavin, K ;
Lowell, JA ;
Howard, TK ;
Shenoy, S ;
Burgess, S ;
Dolan, S ;
Kano, JM ;
Mahon, M ;
Schnitzler, MA ;
Woodward, R ;
Irish, W ;
Ramachamdra, V ;
Singer, GG .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (3B) :16S-18S
[7]  
BUNNAPRADIST S, 2003, UCLA IMMUNOGENETICS, P405
[8]   Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients [J].
Bustami, RT ;
Ojo, AO ;
Wolfe, RA ;
Merion, RM ;
Bennett, WM ;
McDiarmid, SV ;
Leichtman, AB ;
Held, PJ ;
Port, FK .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (01) :87-93
[9]   Is there a direct effect of antithymocyte globulin on hematopoiesis? [J].
Chen, GB ;
Kook, H ;
Zeng, WH ;
Young, NS ;
Maciejewski, JP .
HEMATOLOGY JOURNAL, 2004, 5 (03) :255-261
[10]   Cyclosporine prolongs delayed graft function in kidney transplantation: Are rabbit anti-human thymocyte globulins the answer? [J].
Cravedi, P ;
Codreanu, I ;
Satta, A ;
Turturro, M ;
Sghirlanzoni, M ;
Remuzzi, G ;
Ruggenenti, P .
NEPHRON CLINICAL PRACTICE, 2005, 101 (02) :C65-C71